Source comparison
Thymosin Beta 4 vs TB-4: Application Comparison
The table below summarizes the primary distinctions between full-length Thymosin Beta 4 and fragmented TB-4 forms across key research parameters. Molecular Weight ~4,921 Da ~1,815 Da ~446 Da Lower MW = faster tissue diffusion Primary Mechanism G-actin sequestr
This comparison does not assign a generated winner or score.
- The table below summarizes the primary distinctions between full-length Thymosin Beta 4 and fragmented TB-4 forms across key research parameters.
- Molecular Weight
- ~4,921 Da
- ~1,815 Da
- ~446 Da
- Lower MW = faster tissue diffusion
- Primary Mechanism
- G-actin sequestration, ILK activation, VEGF upregulation, NF-κB inhibition
- G-actin sequestration, ILK activation, VEGF upregulation
- Limited actin binding, some anti-fibrotic activity
- Full-length offers broadest pathway coverage
- Angiogenesis Efficacy
- High. 30–50% increased vessel density in ischemic models
- High. Comparable to full-length in capillary sprouting assays
- Moderate. Weaker VEGF induction
- 17-AA fragment matches full-length for angiogenesis
- Anti-Inflammatory Activity
- Strong. NF-κB suppression, 40–60% cytokine reduction
- Moderate. Some cytokine reduction, weaker NF-κB effect
- Minimal. Limited immune modulation
- Full-length required for maximal inflammation control
- Cost per mg (Typical)
- $180–$240
- $80–$120
- $40–$60
- Fragments cost 50–75% less
- Synthesis Complexity
- High. 43-residue SPPS, extensive purification
- Moderate. 17-residue SPPS
- Low. 4-residue SPPS
- Longer sequences = higher failure risk, lower yield